Product Description
CagriSema is a combination therapy consisting of Cagrilintide (an amylin analog) and Semaglutide (a GLP-1 receptor agonist), developed to provide a synergistic effect for weight loss and metabolic control. It targets both the amylin and GLP-1 pathways, which are involved in appetite regulation, gastric emptying, and blood glucose control. This dual-action formulation offers a new frontier in the treatment of obesity and type 2 diabetes.
Effects:
CagriSema has shown significant weight loss effects, often exceeding those of Semaglutide alone. It reduces hunger and calorie intake, slows gastric emptying, and improves glycemic control. Clinical trials report enhanced satiety, lower blood sugar levels, and improvements in cardiovascular markers. It’s particularly effective for patients with obesity-related insulin resistance.
Side Effects:
Common side effects include nausea, vomiting, constipation, and loss of appetite, which tend to lessen over time. Some users may experience injection site reactions, fatigue, or headache. As with other GLP-1 receptor agonists, a gradual dose increase is recommended to improve tolerability.
Stacking:
CagriSema is used as a standalone therapy due to its powerful dual mechanism. It should not be stacked with other GLP-1 or amylin mimetics unless supervised by a healthcare provider. It pairs best with a calorie-reduced diet and physical activity for optimal results.
EN 
UA